Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report)'s share price gapped up before the market opened on Monday after an insider bought additional shares in the company. The stock had previously closed at $17.65, but opened at $18.51. Pulse Biosciences shares last traded at $19.25, with a volume of 35,220 shares trading hands.
Specifically, Director Robert W. Duggan bought 56,054 shares of the business's stock in a transaction dated Wednesday, December 11th. The stock was acquired at an average price of $17.35 per share, with a total value of $972,536.90. Following the completion of the purchase, the director now directly owns 42,228,057 shares of the company's stock, valued at approximately $732,656,788.95. This trade represents a 0.13 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.
Wall Street Analysts Forecast Growth
Separately, StockNews.com upgraded Pulse Biosciences to a "sell" rating in a report on Thursday.
Read Our Latest Stock Report on PLSE
Pulse Biosciences Price Performance
The stock has a 50 day moving average price of $17.74 and a 200-day moving average price of $16.50.
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last announced its earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same period in the prior year, the business earned ($0.19) EPS.
Hedge Funds Weigh In On Pulse Biosciences
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD purchased a new stake in Pulse Biosciences in the 1st quarter valued at $88,000. Quest Partners LLC acquired a new position in shares of Pulse Biosciences during the 2nd quarter valued at about $91,000. Cetera Advisors LLC purchased a new stake in shares of Pulse Biosciences in the first quarter valued at about $109,000. Rhumbline Advisers increased its position in Pulse Biosciences by 6.7% during the second quarter. Rhumbline Advisers now owns 25,729 shares of the company's stock worth $288,000 after purchasing an additional 1,608 shares during the last quarter. Finally, Franklin Resources Inc. purchased a new position in Pulse Biosciences during the third quarter worth about $378,000. 76.95% of the stock is currently owned by institutional investors and hedge funds.
About Pulse Biosciences
(
Get Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Recommended Stories
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
